Literature DB >> 4076233

Immunoreactivity of monoclonal anti-melanoma antibodies in relation to the amount of radioactive iodine substituted to the antibody molecule.

S Matzku, H Kirchgessner, W G Dippold, J Brüggen.   

Abstract

The damage to monoclonal anti-melanoma antibodies caused by iodination was investigated by comparing the results obtained using the chloramine-T method and the 1,3,4,6-tetrachloro-3 alpha, 6 alpha-diphenyl-glycoluril (IODOGEN) method at different levels of iodine substitution to the molecule. The level of substitution at which losses in immunoreactivity occurred was evaluated in each monoclonal antibody (MAb) studied. This phenomenon was not dependent on the method of substitution, provided that mild conditions of reaction were used. Lineweaver-Burk plots and--in cases of alterations in binding affinity--Scatchard plots were found to provide an adequate description of the binding behaviour of individual MAbs after labelling. Immunoreactivity was shown to be determined not only by the proportion of bona fide reactive MAb molecules, but also by a substitution-dependent decrease in affinity constants. The practical consequences of altered binding parameters were demonstrated by quantitating specific antibody accumulation in melanoma transplants in vivo.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4076233     DOI: 10.1007/BF00279081

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  9 in total

1.  The use of paired labeling in the determination of tumor-localizing antibodies.

Authors:  D PRESSMAN; E D DAY; M BLAU
Journal:  Cancer Res       Date:  1957-10       Impact factor: 12.701

2.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

Authors:  T Lindmo; E Boven; F Cuttitta; J Fedorko; P A Bunn
Journal:  J Immunol Methods       Date:  1984-08-03       Impact factor: 2.303

5.  Radiolabeling of antibodies.

Authors:  W C Eckelman; C H Paik; R C Reba
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

6.  Heterogeneity of primary and metastatic human malignant melanoma as detected with monoclonal antibodies in cryostat sections of biopsies.

Authors:  L Suter; E B Bröcker; J Brüggen; D J Ruiter; C Sorg
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

7.  Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody.

Authors:  W G Dippold; A Knuth; K H Meyer zum Büschenfelde
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

8.  Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies.

Authors:  W G Dippold; K O Lloyd; L T Li; H Ikeda; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

9.  Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies.

Authors:  B S Wilson; K Imai; P G Natali; S Ferrone
Journal:  Int J Cancer       Date:  1981-09-15       Impact factor: 7.396

  9 in total
  9 in total

1.  The binding parameters of radiolabelled monoclonal F (ab')2 and Fab' fragments relative to immunoglobulin G in reactions with surface-bound antigens.

Authors:  J G Fjeld; T E Michaelsen; K Nustad
Journal:  Eur J Nucl Med       Date:  1992

2.  Factors affecting the antigen-antibody reaction.

Authors:  Roberto Reverberi; Lorenzo Reverberi
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

3.  Antibody transport and internalization into tumours.

Authors:  S Matzku; G Moldenhauer; H Kalthoff; S Canevari; M Colnaghi; J Schuhmacher; H Bihl
Journal:  Br J Cancer Suppl       Date:  1990-07

4.  Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody.

Authors:  L Mantovani; S Ménard; D Mezzanzanica; S Miotti; S M Pupa; M I Colnaghi
Journal:  Br J Cancer Suppl       Date:  1990-07

5.  Labeling of monoclonal antibodies with a 67Ga-phenolic aminocarboxylic acid chelate. Part II. Comparison of immunoreactivity and biodistribution of monoclonal antibodies labeled with the 67Ga-chelate or with 131I.

Authors:  S Matzku; J Schuhmacher; H Kirchgessner; J Brüggen
Journal:  Eur J Nucl Med       Date:  1986

6.  Comparative tumour localization properties of radiolabelled monoclonal antibody preparations of defined immunoreactivities.

Authors:  M V Pimm; R W Baldwin
Journal:  Eur J Nucl Med       Date:  1987

7.  Criteria for selecting monoclonal antibodies with respect to accumulation in melanoma tissue.

Authors:  S Matzku; J Brüggen; E B Bröcker; C Sorg
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  In vivo measurement of the association constant of a radio-labelled monoclonal antibody in experimental immunotargeting.

Authors:  J G Fjeld; H B Benestad; T Stigbrand; K Nustad
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

9.  Radiolocalisation and imaging of stably HPLAP-transfected MO4 tumours with monoclonal antibodies and fragments.

Authors:  P G Hendrix; S E Dauwe; A Van De Voorde; E J Nouwen; M F Hoylaerts; M E De Broe
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.